Assyro AI

FDA Orange Book · active-ingredient family

Sarecycline hydrochloride

Sarecycline hydrochloride is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:SEYSARA · NDA 209521

1

Brand (NDA)

0

Generics (ANDA)

4

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
SEYSARARLD×3ALMIRALLNDA 209521Oct 01, 2018

Listed patents (4)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9481639Aug 10, 2028in 2 yr 2 mo
U-2409
8513223Dec 07, 2029in 3 yr 6 mo
U-2406
8318706Jan 03, 2032in 5 yr 7 mo
SubstanceProductU-2405
9255068Feb 09, 2033in 6 yr 9 mo
SubstanceProductU-2407

Sarecycline hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.